Back to Search
Start Over
Guardians at the gate: patent protection of therapeutic monoclonal antibodies through product life cycle management--Part 3.
- Source :
-
MAbs [MAbs] 2009 Nov-Dec; Vol. 1 (6), pp. 600-3. Date of Electronic Publication: 2009 Nov 14. - Publication Year :
- 2009
-
Abstract
- Product life cycle management, which necessarily utilizes a multi-disciplinary approach, is an essential tool for companies that develop or market therapeutic monoclonal antibodies (mAbs). Too little attention to such a plan, or use of the wrong resources, could substantially curtail a product's life span. The most difficult part of the therapeutic antibody business is the development of high-quality, safe and effective products. Great care should thus be taken to ensure that products with these characteristics are positioned in a marketplace that is competition-free for as long as possible. In an era of mAbs with billion dollar markets, the loss of even a single day of sales could cost companies millions of dollars in lost revenue.
- Subjects :
- Antibodies, Monoclonal therapeutic use
Drug Discovery legislation & jurisprudence
Economic Competition legislation & jurisprudence
Humans
Intellectual Property
Marketing legislation & jurisprudence
Patents as Topic
Practice Management
Antibodies, Monoclonal economics
Immunotherapy
Legislation, Drug
Subjects
Details
- Language :
- English
- ISSN :
- 1942-0870
- Volume :
- 1
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- MAbs
- Publication Type :
- Academic Journal
- Accession number :
- 20068401
- Full Text :
- https://doi.org/10.4161/mabs.1.6.10204